Doxazosin Clinical Trials

Size	Price	Qty
25mg	USD 147
1g	USD 970

Clinical Trials

The clinical evaluation of doxazosin encompasses several completed Phase 1, Phase 2, and Phase 4 trials sponsored by pharmaceutical companies such as Pfizer, alongside academic centers and public institutes including the University of Dundee and the National Institute on Drug Abuse. These studies evaluated diverse therapeutic indications, including hypertension, benign prostatic hyperplasia, pheochromocytoma, and allergic rhinitis. Additionally, early-phase research investigated the drug's effects on physiological and subjective responses associated with cocaine addiction.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01946035	Completed	Allergic Rhinitis	University of Dundee	2013-09	Phase 4
NCT01379898	Completed	Pheochromocytoma	University Medical Center Groningen\|Radboud University Medical Center\|UMC Utrecht\|VU University of Amsterdam\|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)\|Leiden University Medical Center\|Erasmus Medical Center\|Maastricht University Medical Center\|St. Antonius Hospital\|Medisch Spectrum Twente\|Maxima Medical Center\|Canisius-Wilhelmina Hospital\|Onze Lieve Vrouwe Gasthuis\|Atrium Medical Center\|Isala	2011-12	Phase 4
NCT01062945	Completed	Cocaine Addiction\|Cocaine Abuse\|Cocaine Dependence\|Substance Abuse	Baylor College of Medicine\|National Institute on Drug Abuse (NIDA)	2010-01	Phase 1
NCT00646841	Completed	Hypertension	Pfizer''s Upjohn has merged with Mylan to form Viatris Inc.\|Pfizer	2003-02	Phase 4
NCT00645034	Completed	Benign Prostatic Hyperplasia	Pfizer''s Upjohn has merged with Mylan to form Viatris Inc.\|Pfizer	2002-11	Phase 2

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Doxazosin product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Doxazosin selectively antagonizes postsynaptic α1-adrenergic receptors, thereby blocking catecholamine-induced intracellular signaling pathways that drive vascular and non-vascular smooth muscle contraction. The resulting inhibition of smooth muscle tone leads to vasodilation and decreased bladder neck resistance, underlying its therapeutic application in clinical conditions such as hypertension, benign prostatic hyperplasia, and pheochromocytoma.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).